NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status (Descending) |
---|---|---|---|---|---|---|---|---|---|---|---|
50090-5657-01 | 50090-5657 | Prednisone | PREDNISONE | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 14, 2021 | In Use | |
50090-5660-00 | 50090-5660 | Prednisone | PREDNISONE | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 14, 2021 | In Use | |
50090-5812-00 | 50090-5812 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Oct. 18, 2021 | In Use | ||
50090-5812-01 | 50090-5812 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Oct. 18, 2021 | In Use | ||
50090-5816-06 | 50090-5816 | PREDNISONE | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 18, 2021 | In Use | |
50228-0306-20 | 50228-0306 | Raloxifene hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Oct. 12, 2016 | In Use | ||
50228-0306-30 | 50228-0306 | Raloxifene hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Oct. 12, 2016 | In Use | ||
51079-0581-01 | 51079-0581 | Leucovorin Calcium | Leucovorin Calcium | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Feb. 26, 1996 | In Use | |
51079-0581-06 | 51079-0581 | Leucovorin Calcium | Leucovorin Calcium | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Feb. 26, 1996 | In Use | |
51655-0726-21 | 51655-0726 | PredniSONE | PredniSONE | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | June 10, 2021 | In Use | |
55154-0450-05 | 55154-0450 | Metoclopramide Hydrochloride | Metoclopramide Hydrochloride | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Dec. 10, 1993 | In Use | |
55154-8329-05 | 55154-8329 | Ondansetron Hydrochloride | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 21, 2012 | In Use | |
55700-0854-21 | 55700-0854 | Dexamethasone | TaperDex 6-day | 1.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 27, 2020 | In Use | |
58181-3040-05 | 58181-3040 | Lomustine | Gleostine | 10.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrosourea | Oral | Aug. 18, 2014 | In Use | |
58181-3041-05 | 58181-3041 | Lomustine | Gleostine | 40.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrosourea | Oral | Aug. 18, 2014 | In Use | |
58181-3042-05 | 58181-3042 | Lomustine | Gleostine | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrosourea | Oral | Aug. 18, 2014 | In Use | |
59923-0604-02 | 59923-0604 | Fludarabine Phosphate | Fludarabine Phosphate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Dec. 31, 2019 | In Use | |
59923-0703-05 | 59923-0703 | temozolomide | TEMOZOLOMIDE | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0704-14 | 59923-0704 | temozolomide | TEMOZOLOMIDE | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0705-05 | 59923-0705 | temozolomide | TEMOZOLOMIDE | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0706-14 | 59923-0706 | temozolomide | TEMOZOLOMIDE | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0707-05 | 59923-0707 | temozolomide | TEMOZOLOMIDE | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0708-14 | 59923-0708 | temozolomide | TEMOZOLOMIDE | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0709-05 | 59923-0709 | temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use | |
59923-0710-14 | 59923-0710 | temozolomide | TEMOZOLOMIDE | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan. 25, 2019 | In Use |
Found 10,000 results in 7 milliseconds — Export these results